Sendai Viral Envelope Vector for Prostate Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for prostatic and melanoma cancers, face challenges in achieving complete remission, with hormone-refractory prostatic cancers showing low response to endocrine therapy and melanoma treatments being ineffective at low doses.
Innovation Solution
The use of an inactivated Sendai viral envelope as a therapeutic agent, which induces apoptosis in tumor cells and activates immune responses, providing a novel approach for treating and preventing prostatic and melanoma cancers by directly targeting cancer cells and enhancing antitumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene introduction, then introduction efficiency is improved, but safety problems arise due to parental virus-derived gene introduction, immunogenicity, and host genome modification
Solution Approach 1:
The patent extracts only the envelope structure from the Sendai virus, separating it from the viral genome and replication machinery. This envelope structure retains membrane fusion capability while eliminating the harmful genetic material, thus achieving both high efficiency and safety
Solution Approach 2:
The Sendai virus envelope acts as an intermediary carrier that mediates gene delivery without introducing viral genetic material. It facilitates membrane fusion and gene transfer while the inactivated viral genome prevents replication and immunogenic responses
2Object-affected harmful factors
If non-viral methods like liposomes are used, then cytotoxicity and immunogenicity are reduced, but gene introduction efficiency becomes lower
Solution Approach 1:
The patent creates a composite structure by combining the Sendai virus envelope with liposomal components. This hybrid structure merges the high efficiency of viral vectors with the low toxicity of non-viral liposomes, achieving both goals simultaneously
Solution Approach 2:
The patent modifies the physical and chemical parameters of the envelope structure through inactivation processes, changing its properties from a replicating virus to a stable, non-infectious delivery vehicle that maintains fusion capability while reducing immunogenicity
3Productivity
If Sendai virus is used for gene delivery, then delivery efficiency is improved, but high immunogenicity and CTL induction occur
Solution Approach 1:
The patent extracts only the envelope structure from the Sendai virus, separating it from the viral genome and replication machinery. This envelope structure retains membrane fusion capability while eliminating the harmful genetic material, thus achieving both high efficiency and safety
Solution Approach 2:
The patent uses the inactivated viral envelope, which would normally be discarded as waste after viral replication, and converts it into a beneficial delivery vehicle. The inactivated genome becomes a safety feature rather than a harmful element
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Sendai viral envelope effectively regresses hormone-refractory prostatic cancers and exhibits a melanoma regression effect at low doses, offering a promising alternative to existing therapies by inducing apoptosis and activating immune responses, thereby addressing the limitations of current cancer treatment methods.
Implementation Method 1
induces apoptosis in tumor cells and activates immune responses
Implementation Method 2
Sendai virus has a minus-stranded RNA about 15,500 bases long as the genome, has RNA polymerase, is unstable to heat, agglutinates almost all kinds of erythrocytes, and exhibits hemolytic nature
Implementation Method 3
activates immune responses, providing a novel approach for treating and preventing prostatic and melanoma cancers by directly targeting cancer cells and enhancing antitumor immunity
Data Source
Figure 1(A)~1(B)
Figure 2
Figure 3
AI summary
Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma tberapautic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided.